VIKING GLOBAL INVESTORS LP: BRIDGEBIO PHARMA INC (BBIO): Quarterly 13F Position History
As of Q4 2025, VIKING GLOBAL INVESTORS LP reported 14,393,934 shares of BRIDGEBIO PHARMA INC (BBIO), worth $1.1B and representing 2.9% of its 13F equity book. Quarter-over-quarter share count change: 1,583,915 (-9.9%) . The position first appeared in Q2 2019 and has been disclosed across 27 13F-HR filings in Pactolio's tracked window.
- 14,393,934Shares Held (Latest Filing)
- $1.1BReported Market Value (Latest Filing)
- 2.9%Portfolio Weight (% of 13F Equity Book)
- 1,583,915Quarter-over-Quarter Share Change
- +$271.1MQuarter-over-Quarter Value Change
- 26,620,991Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 27 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q4 2025 | 14,393,934 | 1,583,915 | -9.9% | $1.1B | 2.9% | $76.5 |
| Q3 2025 | 15,977,849 | 2,577,526 | -13.9% | $829.9M | 2.2% | $51.9 |
| Q2 2025 | 18,555,375 | 3,500,000 | -15.9% | $801.2M | 2.3% | $43.2 |
| Q1 2025 | 22,055,375 | 3,065,616 | -12.2% | $762.5M | 2.4% | $34.6 |
| Q4 2024 | 25,120,991 | 0 | — | $689.3M | 2.2% | $27.4 |
| Q3 2024 | 25,120,991 | 0 | — | $639.6M | 2.3% | $25.5 |
| Q2 2024 | 25,120,991 | 0 | — | $636.3M | 2.4% | $25.3 |
| Q1 2024 | 25,120,991 | 0 | — | $776.7M | 2.9% | $30.9 |
| Q4 2023 | 25,120,991 | 0 | — | $1.0B | 3.7% | $40.4 |
| Q3 2023 | 25,120,991 | 1,500,000 | -5.6% | $662.4M | 2.7% | $26.4 |
| Q2 2023 | 26,620,991 | 0 | — | $457.9M | 1.9% | $17.2 |
| Q1 2023 | 26,620,991 | 0 | — | $441.4M | 2.1% | $16.6 |
| Q4 2022 | 26,620,991 | 0 | — | $202.9M | 1.0% | $7.6 |
| Q3 2022 | 26,620,991 | 0 | — | $264.6M | 1.2% | $9.9 |
| Q2 2022 | 26,620,991 | 0 | — | $241.7M | 1.1% | $9.1 |
| Q1 2022 | 26,620,991 | 0 | — | $270.2M | 1.1% | $10.2 |
| Q4 2021 | 26,620,991 | 0 | — | $444.0M | 1.3% | $16.7 |
| Q3 2021 | 26,620,991 | 0 | — | $1.2B | 3.5% | $46.9 |
| Q2 2021 | 26,620,991 | 0 | — | $1.6B | 4.9% | $61.0 |
| Q1 2021 | 26,620,991 | 0 | — | $1.6B | 4.9% | $61.6 |
| Q4 2020 | 26,620,991 | 0 | — | $1.9B | 5.2% | $71.1 |
| Q3 2020 | 26,620,991 | 0 | — | $998.8M | 3.6% | $37.5 |
| Q2 2020 | 26,620,991 | 0 | — | $868.1M | 3.8% | $32.6 |
| Q1 2020 | 26,620,991 | 0 | — | $772.0M | 4.0% | $29.0 |
| Q4 2019 | 26,620,991 | 0 | — | $933.1M | 4.4% | $35.0 |
| Q3 2019 | 26,620,991 | 0 | — | $571.6M | 3.0% | $21.5 |
| Q2 2019 | 26,620,991 | — | — | $718.0M | 3.2% | $27.0 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did VIKING GLOBAL INVESTORS LP first disclose a BBIO position in 13F-HR filings?
VIKING GLOBAL INVESTORS LP first reported BRIDGEBIO PHARMA INC (BBIO) on its 13F-HR filing for the period ending 2019-06-30 (Q2 2019). The position has appeared on 27 reported quarters within Pactolio's tracked window.
What was VIKING GLOBAL INVESTORS LP's most recent quarter-over-quarter share-count change in BBIO?
Between Q3 2025 and Q4 2025, VIKING GLOBAL INVESTORS LP reduced its BBIO position by 1,583,915 shares (-9.9%), leaving 14,393,934 shares at a market value of $1.1B.
Does the implied price-per-share represent VIKING GLOBAL INVESTORS LP's cost basis in BBIO?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.